Archimedes Pharma Senior Management Team
Strong leadership with extensive experience and proven track–record for success
Archimedes Pharma’s management team has extensive operational, commercial, development, and financial experience. The Senior Management Team is responsible for providing global strategic direction to ensure both short and long–term growth.
Under the leadership of Jeffrey H. Buchalter, who was appointed President and Chief Executive Officer of Archimedes Pharma in March 2010, the company has experienced tremendous growth including the FDA approval of Lazanda®, the innovative fentanyl nasal spray using the company’s patented PecSys® technology, as well as the market authorization and launch of the product in five key European countries, where it is known as PecFent®. In addition to driving the growth of the company in key European markets, Buchalter has also established Archimedes Pharma’s U.S. commercial operations in Bedminster, New Jersey. Concurrent with the appointment of Mr. Buchalter, the company announced a financing of $100 million; the largest raised by a private European biopharmaceutical company in the past 15 years.
Jeffrey H. Buchalter
President and Chief Executive Officer
Jeffrey H. Buchalter has more than 20 years of industry experience at several multinational pharmaceutical companies where he directed the development and commercialization of numerous pharmaceutical products that meet the needs of patients and healthcare professionals worldwide. Prior to joining Archimedes Pharma, Buchalter was President and CEO of Enzon Pharmaceuticals, Inc., a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for patients with cancer and other life-threatening conditions. He also served as Chairman of the Board of Directors until May 2009.
Prior to joining Enzon in 2004, Mr. Buchalter served as President and CEO of ILEX Oncology, Inc., where he led the company’s transformation into a product–driven pharmaceutical company with a high quality oncology franchise. Genzyme Corporation acquired ILEX Oncology in December 2004 for $1.1 billion.
Among his numerous professional honors, Buchalter received the American Cancer Society’s Joseph F. Buckley Memorial Award for commitment to cancer control and involvement in the oncology pharmaceutical field and was invited by former President George Bush to serve as a partner in the National Dialogue on Cancer initiative. As a strong advocate in accelerating the development of novel new therapeutics for children diagnosed with cancer, Buchalter served as Chairman to the Board of Trustees of The National Childhood Cancer Foundation.
Buchalter currently serves as member of the Board of Directors of TopoTarget A/S, a publicly held Danish biopharmaceutical company and has also held leadership positions at Wyeth, Schering Plough and Pharmacia where he was Group Vice President and Head of the Worldwide Oncology Franchise.
Buchalter earned a B.S. in finance from Seton Hall University and his M.B.A. in marketing from Temple University.
Robert A. DeLuca
Executive VP, Chief Commercial Officer
Robert DeLuca joined Archimedes Pharma as Executive Vice President, Chief Commercial Officer in January 2011 and is responsible for global business development and strategic marketing. DeLuca also leads U.S. Marketing, Managed Care and Sales/Sales Operations, including playing a vital role in preparing and implementing the commercial strategies and plans for the US launch of Lazanda® (fentanyl nasal spray).
DeLuca brings to Archimedes a demonstrated track record of success in the pharmaceutical industry with a combined background in marketing, managed care and sales. He has progressed through senior commercial roles of increasing responsibility at Schering Plough, Berlex, Pharmacia and Sanofi–Aventis. Most recently, Mr. DeLuca held the position of Vice President of US Managed Markets (USMM) at Sanofi–Aventis U.S.
DeLuca is a New Jersey licensed pharmacist and graduated from St. John’s University in New York City. He practiced retail pharmacy for three years post licensure prior to entering the corporate arena. DeLuca also is on the St. John’s College of Pharmacy Advisory Board, serves on the Foundation for Managed Care Pharmacy Board of Trustees, and has memberships in the Academy of Managed Care Pharmacy (AMCP) and in the American Pharmacists Association.
Executive VP, Chief Development Officer
Dr. Michael Perelman joined Archimedes Pharma as Executive Vice President, Chief Development Officer in August 2010. He oversees all development activities, including Clinical Research, Regulatory Affairs, Project Management, and a R&D group based in Nottingham, UK. Dr. Perelman trained as a physician, with a specialty in cardiology, and has more than 25 years experience in the pharmaceutical industry.
Prior to joining Archimedes Pharma, Dr. Perelman spent 14 years at Schering–Plough where he gained expertise in Regulatory Affairs and Program Leadership. As VP/Senior Project Leader he led the development activities within the company’s Cardiovascular and Respiratory franchises. Before joining Schering–Plough, Dr. Perelman worked as a Reviewer within the UK Regulatory Authority and as a Rapporteur across Europe. Dr. Perelman has also held positions at the Astra Clinical Research Unit, Glaxo Group Research, and Squibb.
Dr. Perelman earned his BA, MA, MB, and B Chir from Cambridge University, UK and the Diploma of Pharmaceutical Medicine from the Royal College of Physicians in London. He was appointed FRCP and FFPM in 1996.
Charles A. Reinhart III
Executive Vice President, Chief Financial Officer
Charles A. Reinhart III, joined Archimedes Pharma in September 2011 with 30 years of diversified experience in executive management, strategic planning, debt and equity financing, investor relations, business development, accounting and financial reporting, tax, treasury, financial planning and analysis, and risk management.
Most recently, Reinhart was the CFO and a member of the Executive Management team at PharmAthene, Inc., a leading bio–defense company, where he was responsible for accounting and financial reporting, Sarbanes Oxley (SOX) compliance, financial and strategic planning, IT, and investor relations activities. Prior to joining PharmAthene, Mr. Reinhart served as Senior Vice President of Finance and Corporate Strategy, and was a member of the Operating Leadership Team of Millennium Pharmaceuticals, Inc. While at Millennium, he was responsible for all aspects of the company’s financial and strategic sourcing functions.
Previously, Reinhart was Vice President, Finance at Cephalon, Inc., where he was responsible for worldwide accounting, financial reporting, SOX compliance, tax, treasury and budgeting/forecasting functions. Mr. Reinhart also held finance and public accounting positions at Delsys Pharmaceutical Corporate, Genvec Inc., Dynamic Digital Displays Inc., and Ernst & Young.
Mr. Reinhart is currently on the Board of Directors of VectorLogics Inc., an early stage gene therapy company, as well as a member of the AICPA and PICPA. He is a Certified Public Accountant and earned his Masters of Business Administration from The Wharton School at the University of Pennsylvania and his undergraduate degree in Business and Economics from Lehigh University.
Executive VP, Global Supply Chain
Nick Rothwell joined Archimedes Pharma in July 2010 with more than 30 years experience in the pharmaceutical industry. Prior to joining Archimedes, Rothwell held senior level positions of increasing responsibility with Novartis, Pharmacia, and Wyeth Pharmaceuticals. Mr. Rothwell is a recognized leader in developing, implementing, and managing end–to–end integrated supply chain solutions and specializes in improving the overall performance of the supply chain. Mr. Rothwell has had actual "hands on" experience in all the classical disciplines of Supply Chain Management. He earned a technical degree in Materials Management while serving in the Royal Air Force and is certified in Production & Inventory Management by APICS, The Association for Operations Management.